Cost-effectiveness of heart failure therapies

Nature Reviews Cardiology

Volumn 10, Issue 6, 2013, Pages 338-354

  Rohde, Luis E ^a   Bertoldi, Eduardo G ^a   Goldraich, Livia ^a   Polanczyk, Carísi A ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; ENALAPRIL; EPLERENONE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL SUCCINATE; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; RAMIPRIL; SPIRONOLACTONE; VALSARTAN;

ASSISTED CIRCULATION; CARDIAC RESYNCHRONIZATION THERAPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TERMINAL CARE;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEFIBRILLATORS, IMPLANTABLE; DRUG COSTS; ELECTRIC COUNTERSHOCK; HEALTH CARE COSTS; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL COSTS; HUMANS; MODELS, ECONOMIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879086372     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.60     Document Type: Review

References (133)

1. Rathi, S. & Deedwania, P. C. The epidemiology and pathophysiology of heart failure. Med. Clin. North Am. 96, 881-890 (2012).
2. Stewart, S., MacIntyre, K., Capewell, S. & McMurray, J. J. Heart failure and the aging population: an increasing burden in the 21st century? Heart 89, 49-53 (2003).
3. Heidenreich, P. A. et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933-944 (2011).
4. Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30-41 (2011).
5. Schmidt, M. I. et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet 377, 1949-1961 (2011).
6. Braunschweig, F., Cowie, M. R. & Auricchio, A. What are the costs of heart failure? Europace 13, ii13-ii17 (2011).
7. Teng, T. H., Finn, J., Hobbs, M. & Hung, J. Heart failure: incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005. Circ. Heart Fail. 3, 236-243 (2010).
8. Hunt, S. A. et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, e391-e479 (2009).
9. Araujo, D. V., Tavares, L. R., Verissimo, R., Ferraz, M. B. & Mesquita, E. T. Cost of heart failure in the Unified Health System [Portuguese]. Arq. Bras. Cardiol. 84, 422-427 (2005).
10. Mark, D. B. & Hlatky, M. A. Medical economics and the assessment of value in cardiovascular medicine: Part I. Circulation 106, 516-520 (2002).
11. Miller, W., Robinson, L. A. & Lawrence, R. S. (Eds) Valuing Health for Regulatory Cost-Effectiveness Analysis (National Academies Press, 2006).
12. Arnold, S. V., Cohen, D. J. & Magnuson, E. A. Cost-effectiveness of oral antiplatelet agents-current and future perspectives. Nat. Rev. Cardiol. 8, 580-591 (2011).
13. Sun, X., Wang, L. & Li, Y. Methodological issues in cost-effectiveness studies: a brief overview. J. Evid. Based Med. 3, 201-204 (2010).
14. Barbieri, M. et al. What do international pharmacoeconomic guidelines say about economic data transferability? Value Health 13, 1028-1037 (2010).
15. Weintraub, W. S., Cole, J. & Tooley, J. F. Cost and cost-effectiveness studies in heart failure research. Am. Heart J. 143, 565-576 (2002).
16. Drummond, M. Pharmacoeconomics: friend or foe? Ann. Rheum. Dis. 65 (Suppl. 3), iii44-iii47 (2006).
17. Eichler, H. G., Kong, S. X., Gerth, W. C., Mavros, P. & Jönsson, B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518-528 (2004).
18. Clement, F. M. et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada. JAMA 302, 1437-1443 (2009).
19. Appleby, J., Devlin, N., Parkin, D., Buxton, M. & Chalkidou, K. Searching for cost effectiveness thresholds in the NHS. Health Policy 91, 239-245 (2009).
20. Torosoff, M., Sader, C. & Philbin, E. in Cardiovascular Health Care Economics (Ed.Weintraub, W. S.) 529-584 (Humana Press, 2003).
21. Mejhert, M. Long-term health-care consumption and cost expenditure in systolic heart failure. Eur. J. Intern. Med. 24, 260-265 (2013).
22. Rohde, L. E. et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int. J. Cardiol. 102, 71-77 (2005).
23. Jaarsma, T. et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch. Intern. Med. 168, 316-324 (2008).
24. Postmus, D. et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am. Heart J. 162, 1096-1104 (2011).
25. Chan, D. C., Heidenreich, P. A., Weinstein, M. C. & Fonarow, G. C. Heart failure disease management programs: a cost-effectiveness analysis. Am. Heart J. 155, 332-338 (2008).
26. Miller, G., Randolph, S., Forkner, E., Smith, B. & Galbreath, A. D. Long-term cost-effectiveness of disease management in systolic heart failure. Med. Decis. Making 29, 325-333 (2009).
27. Chen, Y.-H. et al. Assessment of the clinical outcomes and cost-effectiveness of the management of systolic heart failure in Chinese patients using a home-based intervention. J. Int. Med. Res. 38, 242-252 (2010).
28. Hebert, P. L. et al. Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. Ann. Intern. Med. 149, 540-548 (2008).
29. Adlbrecht, A. et al. Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur. J. Clin. Invest. 41, 315-322 (2011).
30. Smith, B., Hughes-Cromwick, P. F., Forkner, E. & Galbreath, A. D. Cost-effectiveness of telephonic disease management in heart failure. Am. J. Manag. Care 14, 106-115 (2008).
31. Gregory, D. et al. Hospital cost effect of a heart failure disease management program: the Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) trial. Am. Heart J. 151, 1013-1018 (2006).
32. Göhler, A. et al. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programs in chronic heart failure. Eur. J. Heart Fail. 10, 1026-1032 (2008).
33. Wijeysundera, H. C. et al. Cost-effectiveness of specialized multidisciplinary heart failure clinics in Ontario, Canada. Value Health 13, 915-921 (2010).
34. Reed, S. D. et al. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial an exercise training study of patients with chronic heart failure. Circ. Cardiovasc. Qual. Outcomes 3, 374-381 (2010).
35. Kühr, E. M., Ribeiro, R. A., Rohde, L. E. & Polanczyk, C. A. Cost-effectiveness of supervised exercise therapy in heart failure patients. Value Health 4 (5 Suppl. 1), S100-S107 (2011).
36. Tavazzi, L. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial. Lancet 372, 1223-1230 (2008).
37. Cowie, M. R. et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modeling in a UK setting. Eur. J. Heart Fail. 13, 681-689 (2011).
38. Jessup, M. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, 1977-2016 (2009).
39. McMurray, J. J. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-847 (2012).
40. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2, 755-763 (1983).
41. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).
42. Riegger, G. A. for the Quinapril Research Group. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur. Heart J. 12, 705-711 (1991).
43. Cohn, J. N. et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
44. Paul, S. D., Kuntz, K. M., Eagle, K. A. & Weinstein, M. C. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch. Intern. Med. 154, 1143-1149 (1994).
45. Tsevat, J. et al. Cost-effectiveness of captopril therapy after myocardial infarction. J. Am. Coll. Cardiol. 26, 914-919 (1995).
46. Glick, H. et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial. J. Card. Fail. 1, 371-380 (1995).
47. Butler, J. R. & Fletcher, P. J. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust. N. Z. J. Med. 26, 89-95 (1996).
48. Erhardt, L., Ball, S., Andersson, F., Bergentoft, P. & Martinez, C. Cost-effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics 12, 256-266 (1997).
49. Schädlich, P. K., Huppertz, E. & Brecht, J. G. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 14, 653-669 (1998).
50. Maggioni, A. P. et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll. Cardiol. 40, 1414-1421 (2002).
51. Bangalore, S., Kumar, S. & Messerli, F. H. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am. J. Med. 123, 1016-1030 (2010).
52. Pradelli, L., Iannazzo, S. & Zaniolo, O. The cost-effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model. Am. J. Cardiovasc. Drugs 9, 383-392 (2009).
53. Bristow, M. R. et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94, 2807-2816 (1996).
54. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13 (1999).
55. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
56. Dargie, H. J. for the CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, 1385-1390 (2001).
57. Packer, M. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
58. Flather, M. D. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215-225 (2005).
59. Yao, G. et al. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics 26, 879-889 (2008).
60. Butler, J. et al. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J. Card. Fail. 18, 265-281 (2012).
61. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
62. Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
63. Tilson, L., McGowan, B., Ryan, M. & Barry, M. Cost-effectiveness of spironolactone in patients with severe heart failure. Ir. J. Med. Sci. 172, 70-72 (2003).
64. Weintraub, W. S. et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 111, 1106-1113 (2005).
65. Szucs, T. D. et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction-an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc. Drugs Ther. 20, 193-204 (2006).
66. de Pouvourville, G., Solesse, A. & Beillat, M. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study. Arch. Cardiovasc. Dis. 101, 515-521 (2008).
67. Zhang, Z. et al. Cost-effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am. J. Cardiovasc. Drugs 10, 55-63 (2010).
68. Chatterjee, S. et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am. J. Med. 125, 817-825 (2012).
69. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717 (1999).
70. McKenna, C. et al. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. Value Health 15, 420-428 (2012).
71. Ward, R. E., Gheorghiade, M., Young, J. B. & Uretsky, B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J. Am. Coll. Cardiol. 26, 93-101 (1995).
72. Angus, D. C. et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 112, 3745-3753 (2005).
73. Rosen, V. M. et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive-heart failure and coronary heart disease in the US. Pharmacoeconomics 28, 47-60 (2010).
74. Moss, A. J. et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 335, 1933-1940 (1996).
75. Buxton, A. E. et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 341, 1882-1890 (1999).
76. Bardy, G. H. et al. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225-237 (2005).
77. Kadish, A. et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med. 350, 2151-2158 (2004).
78. Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877-883 (2002).
79. Mushlin, A. I. et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97, 2129-2135 (1998).
80. Sanders, G. D., Hlatky, M. A. & Owens, D. K. Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med. 353, 1471-1480 (2005).
81. Al-Khatib, S. M. et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann. Intern. Med. 142, 593-600 (2005).
82. National Institute for Health and Care Excellence. Technology Appraisal 95. Implantable cardioverter defibrillators for arrhythmias: review of technology appraisal 11 [online], http://www.nice.org.uk/nicemedia/live/11566/ 33167/33167.pdf (2006).
83. Gandjour, A., Holler, A., Dipl-Ges-Ök & Adarkwah, C. C. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II). Value Health 14, 812-817 (2011).
84. Smith, T. et al. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: an European analysis. Eur. Heart J. 34, 211-219 (2013).
85. Ribeiro, R. A. et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. Value Health 13, 160-168 (2010).
86. Feingold, B., Arora, G., Webber, S. A. & Smith, K. J. Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy. J. Card. Fail. 16, 734-741 (2010).
87. Sanders, G. D., Kong, M. H., Al-Khatib, S. M. & Peterson, E. D. Cost-effectiveness of implantable cardioverter defibrillators in patients > or = 65 years of age. Am. Heart J. 160, 122-131 (2010).
88. Connolly, S. J. et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur. Heart J. 21, 2071-2078 (2000).
89. O'Brien, B. J. et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 103, 1416-1421 (2001).
90. Larsen, G. et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 105, 2049-2057 (2002).
91. Ezekowitz, J. A., Armstrong, P. W. & McAlister, F. A. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann. Intern. Med. 138, 445-452 (2003).
92. Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140-2150 (2004).
93. Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539-1549 (2005).
94. Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361, 1329-1338 (2009).
95. Tang, A. S. et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363, 2385-2395 (2010).
96. Fox, M. et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol. Assess. 11, iii-iv, ix-248 (2007).
97. Callejo, D., Guerra, M., Hernandez-Madrid, A. & Blasco, J. A. Economic assessment of cardiac resynchronization therapy. Rev. Esp. Cardiol. 63, 1235-1243 (2010).
98. Blomstrom, P. et al. Cost-effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. Eur. J. Heart Fail. 10, 869-877 (2008).
99. Maniadakis, N. et al. Cost-effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial. Europace 13, 1597-1603 (2011).
100. Bertoldi, E. G., Rohde, L. E., Zimerman, L. I., Pimentel, M. & Polanczyk, C. A. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system. Int. J. Cardiol. 163, 309-315 (2013).
101. Feldman, A. M. et al. Cost-effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J. Am. Coll. Cardiol. 46, 2311-2321 (2005).
102. Aidelsburger, P., Grabein, K., Klauss, V. & Wasem, J. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective. Clin. Res. Cardiol. 97, 89-97 (2008).
103. Digiorgi, P. L. et al. Heart transplant and left ventricular assist device costs. J. Heart Lung Transplant. 24, 200-204 (2005).
104. Evans, R. W. Cost-effectiveness analysis of transplantation. Surg. Clin. North Am. 66, 603-616 (1986).
105. Ouwens, J. P. et al. The cost-effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands. Transpl. Int. 16, 123-127 (2003).
106. Dayton, J. D., Kanter, K. R., Vincent, R. N. & Mahle, W. T. Cost-effectiveness of pediatric heart transplantation. J. Heart Lung Transplant. 25, 409-415 (2006).
107. Kirk, R. et al. The Registry of the International Society for Heart and Lung Transplantation: fourteenth pediatric heart transplantation report-2011. J. Heart Lung Transplant. 30, 1095-1103 (2011).
108. Rose, E. A. et al. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345, 1435-1443 (2001).
109. Miller, L. W. et al. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med. 357, 885-896 (2007).
110. John, R. et al. Improved survival and decreasing incidence of adverse events with the Heart Mate II left ventricular assist device as bridge-to-transplant therapy. Ann. Thorac. Surg. 86, 1227-1234 (2008).
111. Slaughter, M. S. et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361, 2241-2251 (2009).
112. Slaughter, M. S. & Rogers, J. G. Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support. J. Heart Lung Transplant. 31, 448-449 (2012).
113. Hutchinson, J. et al. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure. Expert Rev. Cardiovasc. Ther. 6, 175-185 (2008).
114. Moreno, S. G., Novielli, N. & Cooper, N. J. Cost-effectiveness of the implantable Heart Mate II left ventricular assist device for patients awaiting heart transplantation. J. Heart Lung Transplant. 31, 450-458 (2012).
115. Clegg, A. J. et al. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation. Health Technol. Assess. 9, 1-132, iii-iv (2005).
116. Clegg, A. J. et al. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int. J. Technol. Assess. Health Care 23, 261-268 (2007).
117. Brown, K. L. et al. Cost utility evaluation of extracorporeal membrane oxygenation as a bridge to transplant for children with end-stage heart failure due to dilated cardiomyopathy. J. Heart Lung Transplant. 28, 32-38 (2009).
118. Reed, S. D. et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 148, 122-128 (2004).
119. McMurray, J. J. et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J. 27, 1447-1458 (2006).
120. Colombo, G. L., Caruggi, M., Ottolini, C. & Maggioni, A. P. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vasc. Health Risk Manag. 4, 223-234 (2008).
121. Taylor, M., Scuffham, P. A., Chaplin, S. & Papo, N. L. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. Value Health 12, 459-465 (2009).
122. Delea, T. E., Vera-Llonch, M., Richner, R. E., Fowler, M. B. & Oster, G. Cost effectiveness of carvedilol for heart failure. Am. J. Cardiol. 83, 890-896 (1999).
123. Caro, J. J. et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J. Card. Fail. 11, 647-656 (2005).
124. Di Stasi, F., Scalone, L., De Portu, S., Menditto, E. & Mantovani, L. G. Cost-effectiveness analysis of bisoprolol treatment for heart failure. Ital. Heart J. 6, 950-955 (2005).
125. Gutzwiller, F. S. et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur. J. Heart Fail. 14, 782-790 (2012).
126. Caro, J. J., Ward, A., Deniz, H. B., O'Brien, J. A. & Ehreth, J. L. Cost-benefit analysis of preventing sudden cardiac deaths with an implantable cardioverter defibrillator versus amiodarone. Value Health 10, 13-22 (2007).
127. Neyt, M., Thiry, N., Ramaekers, D. & Van Brabandt, H. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl. Health Econ. Health Policy 6, 67-80 (2008).
128. Deniz, H. B., Ward, A., Jaime Caro, J., Alvarez, P. & Sadri, H. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada. Curr. Med. Res. Opin. 25, 617-626 (2009).
129. Nichol, G., Kaul, P., Huszti, E. & Bridges, J. F. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann. Intern. Med. 141, 343-351 (2004).
130. Yao, G. et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter- defibrillator. Eur. Heart J. 28, 42-51 (2007).
131. Neyt, M. et al. Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model. BMJ Open 1, e000276 (2011).
132. Noyes, K. et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J. Cardiovasc. Electrophysiol. 24, 66-74 (2013).
133. Sharples, L. D. et al. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). J. Heart Lung Transplant. 25, 1336-1343 (2006).